Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Paratek Pharmaceuticals Inc    PRTK

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
20.5(c) 20.75(c) 20.4(c) 19.7(c) 19.45 Last
358 187 349 987 236 237 315 728 245 330 Volume
+3.54% +1.22% -1.69% -3.43% -1.27% Change
More quotes
Financials ($)
Sales 2017 12,1 M
EBIT 2017 -90,8 M
Net income 2017 -94,1 M
Finance 2017 51,6 M
Yield 2017 -
Sales 2018 22,1 M
EBIT 2018 -92,6 M
Net income 2018 -95,8 M
Finance 2018 17,8 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 40,9x
EV / Sales2018 24,0x
Capitalization 547 M
More Financials
Company
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.Its products include Omadacycline and Sarecycline.The company was founded in February 2001 and is... 
More about the company
Surperformance© ratings of Paratek Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PARATEK PHARMACEUTICALS IN
08/09 PARATEK PHARMACEUTICALS : to Present at Wedbush PacGrow Healthcare Conference
08/09 PARATEK PHARMACEUTICALS INC. : to Present at Wedbush PacGrow Healthcare Conferen..
08/08 Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Confer..
08/04 PARATEK PHARMACEUTICALS, INC. (NASDA : PRTK) Files An 8-K Departure of Directors..
08/04 PARATEK PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Finan..
08/02 PARATEK PHARMACEUTICALS : Announces Inducement Grants under NASDAQ Listing Rule ..
08/02 PARATEK PHARMACEUTICALS : Announces Inducement Grants under NASDAQ Listing Rule ..
08/02 PARATEK PHARMACEUTICALS : reports 2Q loss
08/02 Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results a..
08/02 PARATEK PHARMACEUTICALS INC : Investor Network: Paratek Pharmaceuticals Inc. to ..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/17Pictet Asset Management Ltd. Invests $6.96 Million in Paratek Pharmaceuticals.. 
08/16Paratek Pharmaceuticals (PRTK) Presents At Wedbush PacGrow Healthcare Confere.. 
08/13TIAA CREF Investment Management LLC Has $1.45 Million Position in Paratek Pha.. 
08/11Paratek Pharmaceuticals, Inc. $PRTK Stake Increased by C WorldWide Group Hold.. 
08/10Paratek Pharmaceuticals’ $PRTK “Overweight” Rating Reaffirmed at Cantor Fitzg.. 
More tweets
Qtime:12
News from SeekingAlpha
08/16 Paratek Pharmaceuticals (PRTK) Presents At Wedbush PacGrow Healthcare Confere..
08/12 Tracking Seth Klarman's Baupost Group Holdings - Q2 2017 Update
08/02 Paratek Pharmaceuticals' (PRTK) CEO Michael Bigham on Q2 2017 Results - Earni..
08/02 Paratek Pharmaceuticals beats by $0.23, beats on revenue
07/28 PARATEK : Beware Of The Experts
Chart PARATEK PHARMACEUTICALS IN
Duration : Period :
Paratek Pharmaceuticals In Technical Analysis Chart | PRTK | US6993743029 | 4-Traders
Technical analysis trends PARATEK PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 43,5 $
Spread / Average Target 121%
EPS Revisions
Managers
NameTitle
Michael F. Bigham Chairman & Chief Executive Officer
Evan Loh President, COO, Director & CMO
Douglas W. Pagán Chief Financial & Accounting Officer
Paul McGovern Vice President-Clinical & Medical Affairs
Thomas John Dietz Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PARATEK PHARMACEUTICALS INC32.47%547
AMGEN14.77%122 447
CELGENE CORPORATION10.22%99 812
GILEAD SCIENCES1.02%94 471
REGENERON PHARMACEUTICALS27.64%49 721
VERTEX PHARMACEUTICALS101.63%37 450